Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,786 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A novel natural compound, a cycloanthranilylproline derivative (Fuligocandin B), sensitizes leukemia cells to apoptosis induced by tumor necrosis factor related apoptosis-inducing ligand (TRAIL) through 15-deoxy-Delta 12, 14 prostaglandin J2 production.
Hasegawa H, Yamada Y, Komiyama K, Hayashi M, Ishibashi M, Sunazuka T, Izuhara T, Sugahara K, Tsuruda K, Masuda M, Takasu N, Tsukasaki K, Tomonaga M, Kamihira S. Hasegawa H, et al. Blood. 2007 Sep 1;110(5):1664-74. doi: 10.1182/blood-2007-01-068981. Epub 2007 Jun 5. Blood. 2007. PMID: 17551094 Free article. Clinical Trial.
Genome-wide CRISPR screen identifies CDK6 as a therapeutic target in adult T-cell leukemia/lymphoma.
Ishio T, Kumar S, Shimono J, Daenthanasanmak A, Dubois S, Lin Y, Bryant B, Petrus MN, Bachy E, Huang DW, Yang Y, Green PL, Hasegawa H, Maeda M, Goto H, Endo T, Yokota T, Hatanaka KC, Hatanaka Y, Tanaka S, Matsuno Y, Yang Y, Hashino S, Teshima T, Waldmann TA, Staudt LM, Nakagawa M. Ishio T, et al. Among authors: hasegawa h. Blood. 2022 Mar 10;139(10):1541-1556. doi: 10.1182/blood.2021012734. Blood. 2022. PMID: 34818414 Free PMC article.
Genome-wide CRISPR screens identify CD48 defining susceptibility to NK cytotoxicity in peripheral T-cell lymphomas.
Chiba M, Shimono J, Ishio T, Takei N, Kasahara K, Ogasawara R, Ara T, Goto H, Izumiyama K, Otsuguro S, Perera LP, Hasegawa H, Maeda M, Hashino S, Maenaka K, Teshima T, Waldmann TA, Yang Y, Nakagawa M. Chiba M, et al. Among authors: hasegawa h. Blood. 2022 Nov 3;140(18):1951-1963. doi: 10.1182/blood.2022015646. Blood. 2022. PMID: 35921533 Free PMC article.
Impact of p53 aberration on the progression of Adult T-cell Leukemia/Lymphoma.
Tawara M, Hogerzeil SJ, Yamada Y, Takasaki Y, Soda H, Hasegawa H, Murata K, Ikeda S, Imaizumi Y, Sugahara K, Tsuruda K, Tsukasaki K, Tomonaga M, Hirakata Y, Kamihira S. Tawara M, et al. Among authors: hasegawa h. Cancer Lett. 2006 Mar 28;234(2):249-55. doi: 10.1016/j.canlet.2005.03.039. Cancer Lett. 2006. PMID: 15896902
Survey of chemokine receptor expression reveals frequent co-expression of skin-homing CCR4 and CCR10 in adult T-cell leukemia/lymphoma.
Harasawa H, Yamada Y, Hieshima K, Jin Z, Nakayama T, Yoshie O, Shimizu K, Hasegawa H, Hayashi T, Imaizumi Y, Ikeda S, Soda H, Soda H, Atogami S, Takasaki Y, Tsukasaki K, Tomonaga M, Murata K, Sugahara K, Tsuruda K, Kamihira S. Harasawa H, et al. Among authors: hasegawa h. Leuk Lymphoma. 2006 Oct;47(10):2163-73. doi: 10.1080/10428190600775599. Leuk Lymphoma. 2006. PMID: 17071491
Overexpression of Enhancer of zeste homolog 2 with trimethylation of lysine 27 on histone H3 in adult T-cell leukemia/lymphoma as a target for epigenetic therapy.
Sasaki D, Imaizumi Y, Hasegawa H, Osaka A, Tsukasaki K, Choi YL, Mano H, Marquez VE, Hayashi T, Yanagihara K, Moriwaki Y, Miyazaki Y, Kamihira S, Yamada Y. Sasaki D, et al. Among authors: hasegawa h. Haematologica. 2011 May;96(5):712-9. doi: 10.3324/haematol.2010.028605. Epub 2011 Jan 12. Haematologica. 2011. PMID: 21228036 Free PMC article.
3,786 results